Innovative Technology Centre, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
Org Biomol Chem. 2013 Mar 21;11(11):1766-800. doi: 10.1039/c2ob27003j. Epub 2012 Dec 18.
Imatinib (1), nilotinib (2) and dasatinib (3) are Bcr-Abl tyrosine kinase inhibitors approved for the treatment of chronic myelogenous leukemia (CML). This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the aforementioned active pharmaceutical ingredients (API's).
伊马替尼（1）、尼洛替尼（2）和达沙替尼（3）是批准用于治疗慢性髓性白血病（CML）的 Bcr-Abl 酪氨酸激酶抑制剂。本综述从期刊和专利文献中收集信息，提供了一个全面的参考来源，用于制备上述活性药物成分（API）的不同合成方法。
Zotero 插件